
NEUP Stock Forecast & Price Target
NEUP Analyst Ratings
Bulls say
Neuphoria Therapeutics Inc is advancing its drug candidate BNC 210, which has shown significant efficacy in treating social anxiety disorder and post-traumatic stress disorder, as evidenced by positive Phase 2b trial results. Specifically, the trial demonstrated a statistically significant reduction in CAPS-5 total symptom severity at Week 12 and notable improvements in depressive symptoms and sleep quality. Additionally, BNC 210's strong safety profile is supported by extensive patient exposure, with over 1,500 exposures and a considerable number of patients treated beyond 6 and 12 months, reinforcing the company’s prospects in addressing high unmet medical needs in neuropsychiatric disorders.
Bears say
Neuphoria Therapeutics Inc faces a challenging financial outlook primarily due to the potential for failed or inconclusive clinical trials, which can significantly impact the company's ability to secure necessary funding for drug development. The company’s recent valuation has been adversely affected by a low float, raising the risks associated with its market performance. Additionally, ongoing issues with another drug candidate, Lynx1, contribute to this uncertainty, further questioning the prospects for commercial success in addressing the needs of individuals with neuropsychiatric disorders.
This aggregate rating is based on analysts' research of Neuphoria Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
NEUP Analyst Forecast & Price Prediction
Start investing in NEUP
Order type
Buy in
Order amount
Est. shares
0 shares